Effects of citalopram on blood pressure control in depressive patients with hypertension: A randomized clinical trial

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Accounts of Chemical Research Pub Date : 2024-03-13 DOI:10.34172/jcvtr.31849

Hossein Namdar, E. Khani, Sajad Khiali, N. Safaie, Hedieh Ameli, Gholamreza Rahbari Banaeian, Taher Entezari-Maleki

{"title":"Effects of citalopram on blood pressure control in depressive patients with hypertension: A randomized clinical trial","authors":"Hossein Namdar, E. Khani, Sajad Khiali, N. Safaie, Hedieh Ameli, Gholamreza Rahbari Banaeian, Taher Entezari-Maleki","doi":"10.34172/jcvtr.31849","DOIUrl":null,"url":null,"abstract":"Introduction: Since there is a bi‐directional interaction between hypertension and depression, we aimed to evaluate the effects of citalopram administration in the management of hypertension. Methods: A randomized clinical trial was conducted on 72 patients with concomitant depression and hypertension. The intervention group (n=41) received citalopram 20 mg daily plus anti-hypertensive standard treatment, while the control group (n=31) received only the standard treatment. The study’s primary endpoint was in-office blood pressure (BP) measurement at baseline and home BP monitoring in the first and second months after entering the study. Results: There were no significant differences in baseline systolic BP (163.3±19.6 vs.164.2±20.3 mm Hg; P=0.910) and diastolic BP (94.5±13.8 vs. 88.2±14.4; P=0.071). After one month, diastolic BP (82.7±11.7 vs. 77.09±12.2; P=0.023) was significantly higher in the control group compared to the intervention group. Two months after the intervention, systolic BP (133.8±16.5 vs. 124.5±12.4; P=0.009) and diastolic BP (80.7±10.3 vs. 73.7±9.7; P=0.002) were significantly decreased in the intervention group compared to the control group. Conclusion: This study supported the beneficial effects of citalopram in lowering BP in patients with concomitant depression and hypertension.","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":"8 1","pages":""},"PeriodicalIF":16.4000,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/jcvtr.31849","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Since there is a bi‐directional interaction between hypertension and depression, we aimed to evaluate the effects of citalopram administration in the management of hypertension. Methods: A randomized clinical trial was conducted on 72 patients with concomitant depression and hypertension. The intervention group (n=41) received citalopram 20 mg daily plus anti-hypertensive standard treatment, while the control group (n=31) received only the standard treatment. The study’s primary endpoint was in-office blood pressure (BP) measurement at baseline and home BP monitoring in the first and second months after entering the study. Results: There were no significant differences in baseline systolic BP (163.3±19.6 vs.164.2±20.3 mm Hg; P=0.910) and diastolic BP (94.5±13.8 vs. 88.2±14.4; P=0.071). After one month, diastolic BP (82.7±11.7 vs. 77.09±12.2; P=0.023) was significantly higher in the control group compared to the intervention group. Two months after the intervention, systolic BP (133.8±16.5 vs. 124.5±12.4; P=0.009) and diastolic BP (80.7±10.3 vs. 73.7±9.7; P=0.002) were significantly decreased in the intervention group compared to the control group. Conclusion: This study supported the beneficial effects of citalopram in lowering BP in patients with concomitant depression and hypertension.

查看原文本刊更多论文

西酞普兰对抑郁症高血压患者血压控制的影响：随机临床试验

简介由于高血压和抑郁症之间存在双向作用，我们旨在评估服用西酞普兰治疗高血压的效果。研究方法我们对 72 名同时患有抑郁症和高血压的患者进行了随机临床试验。干预组（41 人）每天服用 20 毫克西酞普兰，同时接受抗高血压标准治疗，而对照组（31 人）仅接受标准治疗。研究的主要终点是基线时的诊室血压（BP）测量和进入研究后第一和第二个月的家庭血压监测。研究结果基线收缩压（163.3±19.6 vs. 164.2±20.3 mm Hg；P=0.910）和舒张压（94.5±13.8 vs. 88.2±14.4；P=0.071）无明显差异。一个月后，对照组的舒张压（82.7±11.7 vs. 77.09±12.2；P=0.023）明显高于干预组。干预两个月后，与对照组相比，干预组收缩压（133.8±16.5 vs. 124.5±12.4；P=0.009）和舒张压（80.7±10.3 vs. 73.7±9.7；P=0.002）明显下降。结论本研究支持西酞普兰对同时患有抑郁症和高血压的患者降低血压的有益作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.